Search

Your search keyword '"Taylor, SF"' showing total 51 results

Search Constraints

Start Over You searched for: Author "Taylor, SF" Remove constraint Author: "Taylor, SF" Topic schizophrenia Remove constraint Topic: schizophrenia
51 results on '"Taylor, SF"'

Search Results

1. Catatonia is associated with higher rates of negative affect amongst patients with schizophrenia and schizoaffective disorder.

2. Aberrant Effective Connectivity During Eye Gaze Processing Is Linked to Social Functioning and Symptoms in Schizophrenia.

3. Neurobehavioral indices of gaze perception are associated with social cognition across schizophrenia patients and healthy controls.

4. Structural connectivity of an interoception network in schizophrenia.

6. Modifying a cognitive behavioral suicide prevention treatment for adults with schizophrenia spectrum disorders in community mental health.

7. Dynamic causal modeling of eye gaze processing in schizophrenia.

8. The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

10. Enhancing Psychosis-Spectrum Nosology Through an International Data Sharing Initiative.

11. A Bayesian model comparison approach to test the specificity of visual integration impairment in schizophrenia or psychosis.

12. Eye gaze perception in bipolar disorder: Self-referential bias but intact perceptual sensitivity.

13. Abnormal GABAergic function and face processing in schizophrenia: A pharmacologic-fMRI study.

14. GABA abnormalities in schizophrenia: a methodological review of in vivo studies.

15. Altered attentional and perceptual processes as indexed by N170 during gaze perception in schizophrenia: Relationship with perceived threat and paranoid delusions.

16. Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population.

17. Role of visual integration in gaze perception and emotional intelligence in schizophrenia.

18. Abnormal GABAergic function and negative affect in schizophrenia.

19. Increased distractor vulnerability but preserved vigilance in patients with schizophrenia: evidence from a translational Sustained Attention Task.

20. The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.

21. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.

22. Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments.

23. Self-assessment of psychological stress in schizophrenia: Preliminary evidence of reliability and validity.

24. Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia.

25. Brain mapping biomarkers of socio-emotional processing in schizophrenia.

26. Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs).

27. Emotional experience predicts social adjustment independent of neurocognition and social cognition in schizophrenia.

28. Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in schizophrenia.

29. Topographic analysis of individual activation patterns in medial frontal cortex in schizophrenia.

30. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.

31. Medial frontal hyperactivity in reality distortion.

32. Neural response to emotional salience in schizophrenia.

33. A functional anatomic study of emotion in schizophrenia.

34. Clozapine-associated cardiomyopathy.

35. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects.

36. In vivo measurement of the vesicular monoamine transporter in schizophrenia.

37. Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome.

38. The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia.

39. Symptom correlates of global measures of severity in schizophrenia.

40. Global cerebral blood flow increase reveals focal hypoperfusion in schizophrenia.

41. PET study of greater visual activation in schizophrenia.

42. Biological predictors of suicidality in schizophrenia.

43. Dexamethasone nonsuppression and short rapid eye movement latency in schizophrenia: markers of an affective diathesis?

45. Biological predictors of 1-year outcome in schizophrenia in males and females.

46. Facilitation and interference of selective attention in schizophrenia.

47. Cerebral blood flow activation and functional lesions in schizophrenia.

48. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes.

49. Neuropsychological function and REM sleep in schizophrenic patients.

50. Effect of neuroleptic treatment on polysomnographic measures in schizophrenia.

Catalog

Books, media, physical & digital resources